Investigating sleepiness and OSAS in the HIV population in UK
Research type
Research Study
Full title
Obstructive sleep apnoea syndrome in people living with HIV: How common is this, and can we effectively treat those who are affected?
IRAS ID
237047
Contact name
Marc Lipman
Contact email
Sponsor organisation
Royal Free London NHS Trust
Clinicaltrials.gov Identifier
34902, ISRCTN submission number (full registration awaited)
Duration of Study in the UK
1 years, 3 months, 1 days
Research summary
Excessive daytime sleepiness (EDS) detrimentally affects quality of life and has consistently been recognised in people living with HIV (PLWH). Historically this was attributed to the impaired health-status associated with HIV infection. However, with access to antiretroviral therapy (medication that targets HIV, available since 1996), HIV is managed as a chronic disease with life expectancies similar to the general population. Recent studies show that over 30% of PLWH report EDS. Likely contributory factors include poor sleep hygiene, depression, insomnia, medication side-effects and sleep disordered breathing (SDB). SDB describes a spectrum from simple snoring to obstructive sleep apnoea (OSA), where abnormalities of the upper airway lead to multiple arousals from sleep and thus EDS.
OSA is associated with an increased risk of high blood pressure, diabetes, cardiovascular disease, depression and cognitive impairment. Obstructive sleep apnoea syndrome (OSAS) describes OSA with associated EDS. OSA is a treatable condition, yet an estimated 85% of cases are undiagnosed in the UK. It is not known what proportion of PLWH with EDS may have undiagnosed OSA. As HIV infection is associated with a higher risk of cardiovascular disease, depression and cognitive impairment than the general population, it is vital to identify and treat potential contributory factors. The prevalence of OSA in PLWH in the small number of previous studies has ranged from 5-75%, likely due to differing population demographics and study methodology. There is a paucity of data on associated symptoms and the efficacy of treatment.
In this single site (Royal Free Hospital) observational study, over 15 months, we will determine: 1) By questionnaire, the prevalence of EDS in the outpatient HIV population. 2) By home sleep study, the proportion of sleepy participants who have OSA. 3) By consultation, the acceptability of treatment for OSA in PLWH and its effect on symptoms.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
18/SW/0084
Date of REC Opinion
27 Mar 2018
REC opinion
Further Information Favourable Opinion